Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Number To Know…5,000,000

Executive Summary

$5m is how much Novo Nordisk has invested in bionic pancreas developer, Beta Bionics.

$5m is the amount of cash Novo Nordisk has pumped into Beta Bionics as part of a strategic partnership between the two companies to develop a bionic pancreas that will be compatible with the drug maker’s NovoLog insulins. Beta’s iLet bionic pancreas is designed for automated delivery of insulin alone and insulin and glucagon, and incorporates Dexcom’s continuous glucose monitoring technology and smart algorithm). Beta last year also received a $5m investment from another major insulin drug maker, Eli Lilly.

Meddevicetracker subscribers – click here to get a profile of Beta Bionics and data on iLet.

Not a subscriber? Click here to request your free demo today.

Advertisement

Related Content

Market Intel: Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market

Topics

Advertisement
UsernamePublicRestriction

Register

MT104404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel